Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Utah has one of the nation's lowest rates of prescriptions for anti-obesity GLP-1 drugs like Wegovy and Ozempic — but their ...

Artificial intelligence and GLP-1 weight-loss shots are getting ads alongside traditional Super Bowl fare like fast food and ...

Surgical tweaks for “Ozempic face” are on the rise. The latest report from AAFPRS reveals a 50% increase in facial fat ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Here, we explain the facts behind several more of Robert F. Kennedy Jr.’s claims during his two Senate hearings as nominee ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

He pointed out that certain stocks often experience significant drops after earnings reports, a trend he has observed ...

They're known to aid in blood sugar control and, now, weight loss — but, according to a sweeping new study, the popular GLP-1 ...